HERO findings also confirm fewer cardiovascular events with relugolix More than 96% of men with advanced prostate cancer who were treated with relugolix, an oral, highly selective gonadatropin-releasing hormone (GnRH)...
The first non-surgical treatment option for a rare cancer subtype WASHINGTON — Mitomycin gel (Jelmyto), an alkylating drug, is now FDA-approved as the first non-surgical treatment for low-grade upper tract urothelial...
Algorithm helps identify which patients can be offered fertility-sparing treatment options Using the Proactive Molecular Classifier for endometrial cancer (ProMisE) algorithm to classify patients with endometrial cancer or...
